Neurological syndromes associated with the ingestion of plants and fungi with a toxic component (II). Hallucinogenic fungi and plants, mycotoxins and medicinal herbs;Síndromes neurológicos asociados con el consumo de plantas y hongos con componente tóxico (II). Hongos y plantas alucinógenos, micotoxinas y hierbas medicinales

Revista de Neurologia

Volumn 36, Issue 10, 2003, Pages 951-960

  Carod Artal, Francisco Javier ^a  

^a SARAH NETWORK OF REHABILITATION HOSPITALS   (Brazil)

Author keywords

Hallucinogenic fungi; Medicinal herbs; Mycotoxins; Neurotoxicology; Plants

Indexed keywords

ACONITUM EXTRACT; ALKALOID; BETA CARBOLINE DERIVATIVE; CALLILEPIS LAUREOLA EXTRACT; CANNABIS; HARMALA; KAVA; LYSERGIDE; MESCALINE; MYCOTOXIN; PLANT EXTRACT; PLANT TOXIN; PSILOCYBINE; PSYCHEDELIC AGENT; PSYCHOTROPIC AGENT; TRYPTAMINE; UNCLASSIFIED DRUG;

BRAIN DISEASE; CLAVICEPS PURPUREA; CLINICAL PRACTICE; DISEASE ASSOCIATION; DYSTONIA; ERGOTISM; FOOD; HERB; HUMAN; HYPERICUM PERFORATUM; INTOXICATION; MOULD; MYCOTOXICOSIS; NEUROTOXICITY; NEUROTOXICOLOGY; PAPAVER SOMNIFERUM; PLANT ROOT; REVIEW; SEDATION; SUGARCANE; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DEGENERATIVE DISEASE; FUNGUS; MEDICINAL PLANT; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DYSTONIA; FUNGI; HALLUCINOGENS; HUMANS; MYCOTOXINS; NEURODEGENERATIVE DISEASES; PLANTS, MEDICINAL;

EID: 0037974370     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3610.2003019     Document Type: Review

References (82)

1. Del Brutto OH, Carod Artal FJ, Román GC, Senanayake N. Tropical Neurology. Continuum. Philadelphia: Lippincott Williams & Wilkins; 2002.
2. Spencer PS, Ludolph AC, Kisby GE. Neurologic diseases associated with use of plant components with toxic potential. Environ Res 1993; 62: 106-13.
3. Carod J, Vázquez C. Una visión transcultural de la patología neurológica y mental en una comunidad maya tzeltal de los Altos de Chiapas. Rev Neurol 1996; 24: 848-54.
4. Carod FJ, Vázquez-Cabrera C. Pensamiento mágico y epilepsia en la medicina tradicional indígena. Rev Neurol 1998; 26: 1064-8.
5. Carod-Artal FJ, Vázquez-Cabrera CB. Antropología neurológica entre los indios Kamayurá del Alto Xingú. Rev Neurol 2001; 32: 688-95.
6. Schultes RE, Hoffman A. Plantas de los dioses: orígenes del uso de los alucinógenos. México: Fondo de Cultura Económica; 1982.
7. Riedlinger TJ. Wasson's alternative candidates for soma. J Psychoactive Drugs 1993; 25: 149-56.
8. Brown RT, Bradens NJ. Hallucinogens. Pediatr Clin North Am 1987; 34: 341-7.
9. De Wolff FA, Pennings EJM. Mushrooms and hallucinogens: neurotoxicological aspects. In Vinken PJ, Bruyn GW, eds. Handbook of clinical Neurology. Vol. 21. Intoxications of the nervous system. Part II. Amsterdam: Elsevier Science BV; 1995. p. 35-60.
10. Lemer AG, Gelkopf M, Skladman I, Oyffe I, Finkel B, Sigal M, et al. Flashback and hallucinogen persisting perception disorder: clinical aspects and pharmacological treatment approach. Isr J Psychiatry Relat Sci 2002; 39: 92-9.
11. Benyhe S. Morphine: new aspects in the study of an ancient compound. Life Sci 1994; 55: 969-79.
12. Jeri FR, Sánchez C, Del Pozo T, Fernández M. The syndrome of coca paste. J Psychoactive Drugs 1992; 24: 173-82.
13. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction 1996; 91: 1585-614.
14. Dalmau A, Bergman B, Brismar B. Psychotic disorders among inpatients with abuse of cannabis, amphetamine and opiates. Do dopaminergic stimulants facilitate psychiatric illness? Eur Psychiatry 1999; 14: 366-71.
15. Nahas G, Latour C. The human toxicity of marijuana. Med J Aust 1992; 156: 495-7.
16. Desmarchelier C, Gumi A, Ciccia G, Giulietti AM. Ritual and medicinal plants of the Ese'ejas of the Amazonian rainforest (Madre de Dios, Peru). J Ethnopharmacol 1996; 52: 45-51.
17. Callaway JC, McKenna DJ, Grob CS, Brito GS, Raymon LP, Poland RE, et al. Pharmacokinetics of Hoasca alkaloids in healthy humans. J Ethnopharmacol 1999; 65: 243-56.
18. Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs 1998; 30: 367-9.
19. Mckenna DJ, Towers GHN. On the comparative ethnopharmacology of malpighiceous and myristicaceous hallucinogens. J Psychoact Drugs 1985; 17: 35-9.
20. Strassman RJ, Qualls CR. Dose-response study of N,N,-dimethyltryptamine in humans. Arch Gen Psychiatry 1994; 51: 85-97.
21. De Smet PA. A multidisciplinary overview of intoxicating snuff ritual in the Western hemisphere. J Ethnopharmacol 1985; 13: 3-49.
22. McKenna DJ, Towers GH, Abbott FS. Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens. J Ethnopharmacol 1984; 12: 179-211.
23. Fray Bernardino de Sahagún. Historia General de las cosas de Nueva España. México: Porrúa; 1985.
24. Kovar KA. Chemistry and pharmacology of hallucinogens, entactogens and stimulants. Pharmacopsychiatry 1998; 31 (Suppl 2): 69-72.
25. Peraica M, Radic B, Lucic A, Pavlovic M. Toxic effects of mycotoxins in humans. Bull World Health Organ 1999; 77: 754-66.
26. Tfelt-Hansen P, Saxena PR, Ferrari MD. Ergot alkaloids. In De Wolff FA, ed. Intoxications of the nervous system. Part II. Vol. 21. Handbook ofclinical Neurology. Amsterdan: Elsevier Science BV; 1995. p. 61-78.
27. King B. Outbreak of ergotism in Wollo, Ethiopia. Lancet 1979; 1: 1411.
28. Enriquez E, Rangel A, Velasco CE, Basave MN, López Rodríguez R. Ergotismo por automedicación. Arch Inst Cardiol Mex 2000; 70: 603-8.
29. Spiegel M, Schmidawer C, Kampfl A, Sarcletti M, Poewe W. Cerebral ergotism under treatment with ergotamine and ritonavir. Neurology 2001; 57: 743-4.
30. Montero A, Giovannoni AG, Tvrde PL. Leg ischaemia in a patient receiving ritonavir and ergotamine. Ann Intern Med 1999; 130: 329-30.
31. Krishnamachari KAVR, Bhat RV. Poisoning of ergoty bajra (pearl millet) in man. Indian J Med Res 1976; 64: 1624-8.
32. Tulpule PG, Bhat RV. Food toxins and their implication in human health. Indian J Med Res 1978; 68 (Suppl): S99-108.
33. Liu X, Luo X, Hu W. Studies on epidemiology and etiology of moldy sugarcane poisoning in China. Biom Environ Sci 1992; 5: 161-77.
34. He F, Zhang S, Qian F, Zhang C. Delayed dystonia with striatal CT lucencies induced by a mycotoxin (3-nitropropionic acid). Neurology 1995; 45: 2178-83.
35. Ming L. Moldy sugarcane poisoning: a case report with a brief review. J Toxicol Clin Toxicol 1995; 33: 363-7.
36. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M. 3-nitropropionic-acid exogenous animal neurotoxin and possible human striatal toxin. Canadian J Neurol Sciences 1991; 18: 492-8.
37. Patocka J, Bielavsky J, Cabal J, Fusek J. 3-Nitropropionic acid and similar nitrotoxins. Acta Medica (Hradec Kralove) 2000; 32: 9-13.
38. Petry JJ, Hadley SK. Medicinal herbs: answers and advice, Part 1. Hosp Pract (Off Ed) 2001; 36: 57-60.
39. Petry JJ, Hadley SK. Medicinal herbs: answers and advice. Part 2. Hosp Pract (OffEd) 2001; 36: 55-9.
40. Manteiga R, Park DL, Ali SS. Risks associated with consumption of herbal teas. Rev Environ Contam Toxicol 1997; 150: 1-30.
41. Ernst E. The risk-benefit profile of commonly used herbal therapies: gingko, John's wort, ginseng, echinacea, saw palmetto, and kava. Ann Intern Med 2002; 136: 42-53.
42. Kim HL, Strelzer J, Goebert D. John's wort for depression: a meta-analysis of well-defined clinical trials. J Nervous Mental Dis 1999; 187: 532-8.
43. +. J Pharmacol Exp Ther 1999; 290: 1363-8.
44. Gordon JB. SSRIs and John's wort: possible toxicity? Am Fam Phys 1998; 57: 950-1.
45. Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following traumatic brain injury. Brain injury 2002; 16: 359-67.
46. Schneck C. John's wort and hypomania. J Clin Psychiatry 1998; 56: 689.
47. O'breasail AM, Argouarch S. Hypomania and John's wort. Can J Psychiatry 1998; 43: 746-7.
48. Zafonte RD, Elovic E. St. John's wort. J Head Trauma Rehabil 2001; 16: 519-22.
49. Patel S, Robinson R, Burk M. Hypertensive crisis associated with John's wort. Am J Med 2002; 112: 507-8.
50. Sindrup SH, Madsen C, Bach FW, Gram FW, Gram LF, Jensen TS. St. John's wort has no effect on pain in polyneuropathy. Pain 2001; 91: 361-5.
51. Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and metaanalysis. J Clin Psychopharmacol 2000; 20: 84-9.
52. Pittler MH, Ernst E. Kava extract for treating anxiety (Cochrane review). Cochrane Database Syst Rev 2002; 2: CD003383.
53. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1988; 22: 1105-20.
54. Schelosky L, Raffaud C, Jendroska K, Poewe W. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995; 58: 639-40.
55. Wooltorton E. Herbal kava: reports of liver toxicity. CMAJ 2002; 166: 777.
56. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996; 125: 940-1.
57. Meseguer E, Taboada R, Sánchez V, Mena MA, Campos V, García de Yébenes J. Life-threatening parkinsonism induced by kava kava. Mov Disord 2002; 17: 195-6.
58. Imazio M, Belli R, Pomari F, Cecchi E, Chinaglia A, Graschino G, et al. Malignant ventricular arrythmias due to Aconitum napellus seeds. Circulation 2000; 102: 2907-8.
59. Mizugaki M, Ito K, Ohyama Y, Konishi Y, Tanaka S, Kurusawa K. Quantitative analysis of Aconitum alkaloids in the urine and serum of a male attempting suicide by oral intake of aconite extract. J Anal Toxicol 1998; 22: 336-40.
60. Ameri A. The effects of Aconitum alkaloids on the central nervous system. Prog Neurobiol 1998; 56: 211-35.
61. Wright SN. Irreversible block of human heart (hH1) sodium channels by the plant alkaloid lappaconitine. Mol Pharmacol 2001; 59: 183-92.
62. Chan TY, Tomlinson B, Chan WW, Yeung VT, Tse LK. A case of acute aconitine poisoning caused by chuanwu and caowu. J Trop Med Hyg 1993; 96: 62-3.
63. Chan TY, Tomlinson B, Critchley JA. Aconitine poisoning following the ingestion of Chinese herbal medicines: a report of eight cases. Aust N Z J Med 1993; 23: 268-71.
64. Chan TY, Chan LY, Tam LS, Critchley JA. Neurotoxicity following the ingestion of a Chinese medicinal plant, Alocasia macrorrhiza. Hum Exp Toxicol 1995; 14: 727-8.
65. Popat A, Shear NH, Malkiewicz I, Stewart MJ, Steenkamp V, Thomson S, et al. The toxicity of Callilepis laureola, a South African traditional herbal medicine. Clin Biochem 2001; 34: 229-36.
66. Steenkamp V, Stewart MJ, Zuckerman M. Detection of poisoning by Impila (Callilepis laureola) in a mother and child. Hum Exp Toxicol 1999; 18: 594-7.
67. Laurens JB, Bekker LC, Steenkamp V, Stewart MJ. Gas chromatographic-mass spectometric confirmation of atractyloside in a patient poisoned with Callilepis laureola. J Chromatogr B Biomed Sci Appl 2001; 765: 127-33.
68. Hsieh CL, Tang NY, Chiang SY, Hsieh CT, Lin JG. Anticonvulsive and free radical scavenging actions of two herbs, Uncaria rhynchophylla (MIQ) Jack and Gastrodia elata B1, in kainic acid-treated rats. Life Sci 1999; 65: 2071-82.
69. Akah PA, Nwambie AI, Gamaniel KS, Wambebe C. Experimental study of the anticonvulsant plants used for treatment of infantile convulsion in Nigeria. Brain Res Bull 1997; 44: 611-3.
70. Burkhard PR, Burkhardt K, Haenggeli CA, Landis T. Plant induced seizures: reappearance of an old problem. J Neurol 1999; 246: 667-70.
71. Wada K, Haga M. Food poisoning by Gingko biloba seeds. In Hori T, Ridge RW, Tulecke W, eds. Gingko biloba - a global treasure. Tokio: Springer-Verlag; 1997. p. 309-21.
72. Miwa H, Ijima M, Tanaka S, Mizuno Y. Generalized convulsions after consuming a large amount of gingko nuts. Epilepsia 2001; 42: 280-1.
73. Gregory PJ. Seizure associated with Gingko biloba? Ann Intern Med 2001; 134: 344.
74. Granger AS. Gingko biloba precipitating epileptic seizures. Age ageing 2001; 30: 523-5.
75. Wada K, Ishigaki K, Ueda Y, Sakata M, Haga M. An antivitamin B6, 4′-methylpyridoxin, from the seed of Gingko biloba. Chem Pharm Bull 1985; 33: 3555-7.
76. Arenz A, Klein M, Fiehe K, Grob J, Drewke C, Hemscheidt T, et al. Occurrence of neurotoxic 4′-methylpyridoxine in Gingko biloba leaves, Gingko medications and Japanese Gingko food. Planta Medica 1996; 62: 548-51.
77. Kajiyama Y, Fujii K, Takeuchi H, Manabe Y. Gingko seed poisoning. Pediatrics 2002; 109: 325-7.
78. Vale S. Subarachnoid haemorrhage associated with Gingko biloba. Lancet 1998; 352: 36.
79. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Gingko biloba ingestion. Neurology 1996; 46: 1775-6.
80. Pinto NR, Baruzzi RG. Male pubertal reclusion and risk of death in Indians from Alto Xingu, central Brazil. Hum Biol 1991; 63: 821-34.
81. Chaves N, Lima OG, Teodosio NR, Pessoa W. A 'Mucunã Vermelha' (Dioclea grandifiora Benth) na Nutriçao. Recife: Laboratório de Fisiología. Facultade de Medicina da Universidade de Recife; 1948.
82. Emmerich M, Senna Valle LM. Estudos de etnobotánica no Parque Indígena do Xingu. 1. Uma Periandra (Leguminosae) nova. Boletim do Museu Nacional (Botánica) 1980; 57: 1-3.